 |
|
|
| |
Synergistic Interactions of HCV NS5A Replication Complex Inhibitors Sensitize Resistant Variants
and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) In Vitro and In Vivo
|
| |
| |
Reported by Jules Levin
EASL 2013 April 26 Amsterdam
Gao M, O'Boyle II DR, Lemm JA, Fridell RA, Wang C, Roberts S, Liu M, Nower P, Wang Y-K, Johnson BM, Kramer M, Moulin F, Nophsker MJ, Hewawasam P, Kadow J, Cockett M, Meanwell NA, Belema M, Sun JH
Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
"PXB mice (PhoenixBio) were infected with GT 1a and treated orally with
BMS-393 +/- Syn or Syn alone for up to 2 weeks" from Jules: a synergist molecule has been developed & being studied by BMS in combination with BMS052, their NS5A, which will it is hoped prevent resistance & reverse resistance associated with BMS052 & thus these 2 drugs would be used together as part of a combination oral therapy
|
| |
|
|
|
|
|
